Minimally Invasive Aesthetic Procedures Will Expand International Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 Apr 25

Updated

08 Dec 25

Views

56

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

131.0%

7D

-9.4%

Loading

1Y

131.0%

7D

-9.4%

You can edit this narrative until Dec 9 6:05 PM. Then, changes will post as Updates.

Author's Valuation

US$639.2% undervalued

AnalystConsensusTarget Fair Value

Shared on 08 Dec 25

APYX: Workflow Console Rollout Will Drive Bullish Demand Inflection

Analysts have raised their price target on Apyx Medical to $8.00, citing increasing optimism that the AYON all in one console, which integrates the company's Renuvion technology with multiple surgical offerings, can drive an inflection in demand by streamlining workflows and addressing a large, growing patient base. Analyst Commentary Recent research notes highlight a shift in sentiment as bullish analysts point to AYON as a key driver of Apyx Medical's next phase of growth, underpinning the higher price target.

Shared on 24 Nov 25

Fair value Increased 33%

APYX: Recent Product Launch and Equity Raise Will Drive Share Momentum

Analysts have raised their price target for Apyx Medical from $4.50 to $6.00 per share, citing increased growth prospects supported by the successful launch and strong physician appeal of the AYON system. Analyst Commentary Recent analyst feedback reflects a growing optimism around Apyx Medical's outlook, particularly in light of the momentum generated by the AYON system launch and its integration of legacy technology and new surgical offerings.

Shared on 07 Nov 25

Fair value Increased 13%

APYX: Earnings Guidance Increase Will Drive Market Expansion Opportunities

Narrative Update on Apyx Medical: Analyst Price Target Revision Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.

Shared on 01 May 25

Fair value Increased 8.40%

Shared on 24 Apr 25

Fair value Decreased 7.75%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.1%.

Shared on 17 Apr 25

AnalystConsensusTarget Fair Value

US$6

39.2% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

11.91%

Medical Equipment revenue growth rate

6.82%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.25%

Calculation

US$9.07m

Earnings '28

x

32.73x

PE Ratio '28

=

US$296.71m

Market Cap '28

US$296.71m

Market Cap '28

/

39.62m

No. shares '28

=

US$7.49

Share Price '28

US$7.49 Share Price '28

Discounted to 2025 @ 8.24% p.a.

=

US$5.91

Fair Value '25